Jazz Pharmaceuticals stock surges 50% as analysts bet big on biopharma growth
Jazz Pharmaceuticals has seen its stock climb nearly 50% over the past year. The biopharma firm, valued at $11.64 billion, specialises in neuroscience and oncology treatments. Its shares currently trade at $186.37, well above the 50-day moving average of $175.80. The company's stock reached an all-time high of $198.00 on 1 February. Analysts remain optimistic, with multiple 'Strong Buy' ratings and price targets as high as $275. The Relative Strength Index (RSI) stands at 57.73, while the Weighted Alpha is a strong +55.55.
Most of Jazz Pharmaceuticals' revenue comes from sleep disorder drugs Xywav and Xyrem. However, specific patient numbers for these treatments in 2023 are not publicly available. The stock currently holds a 100% 'Buy' technical rating on our platform.
Jazz Pharmaceuticals continues to attract bullish sentiment from Wall Street. With a market cap of $11.64 billion and strong technical indicators, the company remains a key player in specialty biopharma. The stock's performance reflects confidence in its neuroscience and oncology pipeline.
